Veradermics is also focused on bringing new value to patients and clinicians in the treatment of molluscum contagiosum. Molluscum is a poxvirus infection that affects six million Americans, results in one million doctors’ office visits annually in the U.S., and has no FDA-approved therapeutics. The company is developing VDMC as a first-in-class topical antiviral that was discovered by leading pox virus experts at the University of Pennsylvania and works against a specific molecular target. VDMC was designed to maximize safety for use in the pediatric population affected by molluscum.

Specifically, VDMC has anticipated minimal systemic absorption with topical application, is not expected to result in permanent scarring, and attacks a pox virus target that does not significantly overlap with human DNA synthesis machinery.